Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

ADAM to Launch Human Trials of 3D-Printed Bone

ADAM, a startup company that 3D prints bone, plans to complete pre-clinical trials within the month and commence first human trials by the end of 2019. ADAM, which stands for Advanced Development of Additive Manufacturing, seeks to reduce the cost for synthetic bone production by half. The company is pursuing commercial launch of its core technology in 2020.

ADAM employs additive manufacturing to cut the production cost of synthetic bones from $0.12-$0.15/cm2 down to $0.08. The company performs 3D scanning of bones using its digital platform, then uses Kwambio printers to create bones from the cloud using ceramic bioglass and modified biopolymer in cooperation with certified clinics.

This process obviates the need to take a graft from another bone or bone donor. Once 3D printed, the bone can be implanted into a patient and will ideally dissolve as new bone grows.

Low production costs could enable transplant accessibility to thousands of people each year who delay or forego surgery due to high costs or lack of graft material.

ADAM is also developing Digital Body Atlases. These would allow individuals to take a proactive rather than reactive response to bone damage by having a complete body scan on hand to serve as a blueprint for repair as needed.

Project CEO Volodymyr Usov said, “It’s definitely time to reshape our attitude towards bodies and find new solutions. We are confident that we are doing the right thing for all people, and that is the strongest motivation.”

ADAM, which has offices in Connecticut and Ukraine, has already secured partnerships with ARMI, Stanley Black & Decker and Big Pharma.



Julie A. Vetalice is ORTHOWORLD’s Editorial Assistant.

4 COMMENTS

Security code
Refresh